Help | RSS Feed



Fennec Pharmaceuticals Inc. (NASD:FENC) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Fennec Pharmaceuticals Inc. (NASD:FENC) seasonal charts above shows that a Buy Date of December 13 and a Sell Date of March 4 has resulted in a geometric average return of 15% above the benchmark rate of the S&P 500 Total Return Index over the past 18 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 18 years by an average of 35.9% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

To download FENC seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


Sponsored By...
Seasonal Advantage Portfolio by CastleMoore